

Ramsankar Basak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/796854/publications.pdf>

Version: 2024-02-01

37
papers

619
citations

759233

12
h-index

610901

24
g-index

38
all docs

38
docs citations

38
times ranked

1333
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 1141.	7.4	250
2	Aggressive End-of-Life Care for Metastatic Cancer Patients Younger Than Age 65 Years. Journal of the National Cancer Institute, 2017, 109, .	6.3	51
3	Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men. JAMA Oncology, 2019, 5, 60.	7.1	40
4	Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012. Cancer, 2016, 122, 2234-2241.	4.1	34
5	Medication Adherence Among Recipients with Chronic Diseases Enrolled in a State Medicaid Program. Population Health Management, 2012, 15, 253-260.	1.7	28
6	Stage at presentation and survival outcomes of patients with Gleason 8â€“10 prostate cancer and low prostate-specific antigen. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 119.e19-119.e26.	1.6	25
7	Adherence to Multiple Medications Prescribed for a Chronic Disease: A Methodological Investigation. Journal of Managed Care Pharmacy, 2014, 20, 815-823.	2.2	19
8	Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance. Journal of the National Cancer Institute, 2018, 110, 420-425.	6.3	17
9	Factors influencing prostate cancer treatment decisions for African American and white men. Cancer, 2019, 125, 1693-1700.	4.1	16
10	Comparative Effectiveness of Prostate Cancer Treatment Options: Limitations of Retrospective Analysis of Cancer Registry Data. International Journal of Radiation Oncology Biology Physics, 2019, 103, 1053-1057.	0.8	15
11	Evaluation of the effectiveness of adding androgen deprivation to modern doseâ€“escalated radiotherapy for men with favorable intermediateâ€“risk prostate cancer. Cancer, 2016, 122, 2341-2349.	4.1	14
12	Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States. JAMA Oncology, 2016, 2, 1236.	7.1	13
13	The role of perceived impact on relationship quality in pharmacists' willingness to influence indication-based off-label prescribing decisions. Social Science and Medicine, 2015, 132, 181-189.	3.8	11
14	Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer. European Urology, 2019, 76, 391-397.	1.9	11
15	Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer. Practical Radiation Oncology, 2017, 7, e117-e124.	2.1	10
16	Aggressive care at the end-of-life for younger patients with cancer: Impact of ASCO's Choosing Wisely campaign.. Journal of Clinical Oncology, 2016, 34, LBA10033-LBA10033.	1.6	10
17	Patientâ€“reported sexual quality of life after different types of radical prostatectomy and radiotherapy: Analysis of a populationâ€“based prospective cohort. Cancer, 2019, 125, 3657-3665.	4.1	9
18	Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis. Journal of Urology, 2021, 205, 1444-1451.	0.4	9

#	ARTICLE	IF	CITATIONS
19	Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database. <i>Cancer</i> , 2016, 122, 3069-3074.	4.1	8
20	Patterns and associations of smoking and electronic cigarette use among survivors of tobacco related and non-tobacco related cancers: A nationally representative cross-sectional analysis. <i>Cancer Epidemiology</i> , 2022, 78, 101913.	1.9	8
21	Androgen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer—Reply. <i>JAMA Oncology</i> , 2017, 3, 281.	7.1	4
22	Perceptions of e-cigarette harm among cancer survivors: Findings from a nationally representative survey. <i>Cancer Epidemiology</i> , 2022, 78, 102037.	1.9	4
23	Hospital pharmacistsâ€™ perceived beliefs and responsibilities in indication-based off-label prescribing. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 36-40.	2.1	3
24	Patterns of Recurrence, Detection Rates, and Impact of 18-F Fluciclovine PET/CT on the Management of Men With Recurrent Prostate Cancer. <i>Urology</i> , 2021, 155, 192-198.	1.0	3
25	Comparing algorithms for composite measures of intra-disease multiple medication adherence: The case of diabetes. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1160-1167.	3.0	2
26	Receipt of Guideline-Recommended Surveillance in a Population-Based Cohort of Prostate Cancer Patients Undergoing Active Surveillance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 712-715.	0.8	2
27	Cardiovascular disease and preventive care among cancer survivors: A population-based study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10081-10081.	1.6	1
28	Patient Decision-Making Factors in Aggressive Treatment of Low-Risk Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	2.9	1
29	Non-oncology clinical trial engagement in a nationally representative sample: Identification of motivators and barriers. <i>Contemporary Clinical Trials</i> , 2022, 115, 106715.	1.8	1
30	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1451-1451.	0.4	0
31	Disparity by insurance status and race in receipt of aggressive and advanced treatments for high risk prostate cancer/PCa.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6538-6538.	1.6	0
32	Breast cancer patient functional status and comorbidities and their impact on treatment aggressiveness: A population-based study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 306-306.	1.6	0
33	Does patient preference for sexual function preservation impact treatment choice in prostate cancer? Analysis of a population-based cohort.. <i>Journal of Clinical Oncology</i> , 2016, 34, e18093-e18093.	1.6	0
34	Use of supportive care at end-of-life for patients younger than 65 with incurable cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6514-6514.	1.6	0
35	Factors influencing prostate cancer treatment decisions for African American (AA) and Caucasian (CA) men.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6517-6517.	1.6	0
36	Why are low-risk prostate cancers (PCa) treated aggressively? A population-based cohort analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 127-127.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Security/Privacy Perceptions in Patient Use of Online Medical Records. International Journal of Healthcare Information Systems and Informatics, 2021, 16, 1-18.	0.9	0